Your browser doesn't support javascript.
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva.
Amara, Alieu; Penchala, Sujan Dilly; Else, Laura; Hale, Colin; FitzGerald, Richard; Walker, Lauren; Lyons, Rebecca; Fletcher, Tom; Khoo, Saye.
  • Amara A; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 7SX, UK. Electronic address: A.Amara@liverpool.ac.uk.
  • Penchala SD; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 7SX, UK.
  • Else L; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 7SX, UK.
  • Hale C; The Royal Liverpool & Broadgreen University Hospitals NHS Trust, Prescot Road, Liverpool L7 8XP, UK.
  • FitzGerald R; The Royal Liverpool & Broadgreen University Hospitals NHS Trust, Prescot Road, Liverpool L7 8XP, UK.
  • Walker L; The Royal Liverpool & Broadgreen University Hospitals NHS Trust, Prescot Road, Liverpool L7 8XP, UK.
  • Lyons R; The Royal Liverpool & Broadgreen University Hospitals NHS Trust, Prescot Road, Liverpool L7 8XP, UK.
  • Fletcher T; Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
  • Khoo S; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 7SX, UK; The Royal Liverpool & Broadgreen University Hospitals NHS Trust, Prescot Road, Liverpool L7 8XP, UK.
J Pharm Biomed Anal ; 206: 114356, 2021 Nov 30.
Article in English | MEDLINE | ID: covidwho-1386097
ABSTRACT
In light of the recent global pandemic, Molnupiravir (MPV) or EIDD-2801, developed for the treatment of patients with uncomplicated influenza, is now being trialled for the treatment of infections caused by highly pathogenic coronaviruses, including COVID-19. A sensitive LC-MS/MS method was developed and validated for the simultaneous quantification of MPV and its metabolite ß-d-N4-hydroxycytidine (NHC) in human plasma and saliva. The analytes were extracted from the matrices by protein precipitation using acetonitrile. This was followed by drying and subsequently injecting the reconstituted solutions onto the column. Chromatographic separation was achieved using a polar Atlantis C18 column with gradient elution of 1 mM Ammonium acetate in water (pH4.3) and 1 mM Ammonium acetate in acetonitrile. Analyte detection was conducted in negative ionisation mode using SRM. Analysis was performed using stable isotopically labelled (SIL) internal standards (IS). The m/z transitions were MPV (328.1→126.0), NHC (258.0→125.9) and MPV-SIL (331.0→129.0), NHC-SIL (260.9→128.9). Validation was over a linear range of 2.5-5000 ng/ml for both plasma and saliva. Across four different concentrations, precision and accuracy (intra- and inter-day) were 15%; and recovery of both analytes from plasma and saliva was between 95% and 100% and 65-86% respectively. Clinical pharmacokinetic studies are underway utilising this method for determination of MPV and its metabolite in patients with COVID-19 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Saliva / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Pharm Biomed Anal Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Saliva / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Pharm Biomed Anal Year: 2021 Document Type: Article